Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.4M | $16.8M | $16.1M | $49.6M | $64.9M | $2.57M | $70.0M | $1.30M | $1.76M | $3.02M |
| Revenue growth | — | -13.3% | -4.0% | 208.4% | 30.7% | -96.0% | 2619.1% | -98.1% | 35.3% | 71.6% |
| Gross profit | $15.2M | $14.1M | $13.4M | $43.3M | $48.9M | $1.17M | $68.6M | $1.30M | — | — |
| Gross margin | 78.4% | 84.3% | 83.0% | 87.2% | 75.4% | 45.5% | 98.0% | 100.0% | — | — |
| Operating income | -$90.3M | -$77.6M | -$130M | -$151M | -$156M | -$79.6M | $1.19M | -$8.52M | -$6.11M | -$4.39M |
| Operating margin | -466.3% | -462.7% | -808.8% | -304.6% | -239.8% | -3092.8% | 1.7% | -654.6% | -347.1% | -145.3% |
| Net income | -$89.9M | -$76.9M | -$133M | -$176M | -$184M | -$172M | $112M | -$10.3M | -$2.18M | -$569K |
| Net margin | -464.3% | -458.5% | -823.7% | -354.8% | -282.9% | -6700.9% | 160.1% | -789.4% | -123.9% | -18.8% |
| EPS (diluted) | -$0.46 | -$0.37 | -$0.59 | -$0.72 | -$0.67 | -$21.66 | $11.96 | -$0.99 | -$0.19 | -$0.05 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$69.1M | -$76.2M | -$107M | -$166M | -$159M | -$55.1M | $9.36M | -$23.1M | $1.17M | $2.45M |
| Capital expenditures | $396K | $61.8K | $217K | $2.45M | $207K | $34.0K | — | — | — | — |
| Free cash flow | -$69.5M | -$76.2M | -$107M | -$168M | -$160M | -$55.2M | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $132M | $127M | $162M | $161M | $80.5M | $64.9M | $49.3M | $4.33M | $5.06M | $7.48M |
| Total assets | $142M | $143M | $212M | $266M | $182M | $169M | $90.5M | $43.3M | $38.8M | $37.7M |
| Total liabilities | — | $13.3M | $114M | $257M | $306M | $263M | $55.3M | $14.0M | $11.5M | $10.8M |
| Long-term debt | — | — | $73.4M | $195M | $238M | $0.00 | — | — | — | — |
| Shareholders' equity | $127M | $130M | $97.5M | $9.20M | -$124M | -$93.6M | $35.1M | $29.3M | $27.4M | $26.9M |
| Retained earnings | -$310M | -$387M | -$519M | -$695M | -$879M | -$1.05B | -$939M | -$950M | -$952M | -$952M |
| Shares (wtd avg diluted) | 197M | 216M | 240M | 246M | 276M | 7.96M | 9.37M | 10.4B | 11.5M | 11.6M |
Every figure is extracted from TherapeuticsMD, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.